Anti-nociceptive and anti-allodynic effects of a high affinity NOP hexapeptide [Ac-RY(3-Cl)YRWR-NH2] (Syn 1020) in rodents.

@article{Khroyan2007AntinociceptiveAA,
  title={Anti-nociceptive and anti-allodynic effects of a high affinity NOP hexapeptide [Ac-RY(3-Cl)YRWR-NH2] (Syn 1020) in rodents.},
  author={Taline V. Khroyan and Willma E. Polgar and Juan Ordu{\~n}a and Naunihal Zaveri and Amrit K. Judd and David J. Tuttle and Agust{\'i}n S{\'a}nchez and Lawrence Toll},
  journal={European journal of pharmacology},
  year={2007},
  volume={560 1},
  pages={
          29-35
        }
}
View on PubMed
doi.org
17 Citations
Highly Influential Citations
2
Background Citations
6
Methods Citations
1
Results Citations
2

17 Citations

Differential Effects of Nociceptin/Orphanin FQ (NOP) Receptor Agonists in Acute versus Chronic Pain: Studies with Bifunctional NOP/μ Receptor Agonists in the Sciatic Nerve Ligation Chronic Pain Model in Mice
TLDR
Results indicate that, in mice, circuitry mediating antinociceptive activity in acute and chronic pain states is different, and that supraspinal up-regulation could lead to an attenuation of morphine ant inociception and antiallodynia, which can be alleviated by an NOP receptor antagonist.
Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain.
TLDR
These hybrids represent a promising avenue toward analgesics for the dual treatment of acute and neuropathic pain and showed to be more effective than the parent compounds with respect to hyperalgesia.
SR 16435 [1-(1-(Bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a Novel Mixed Nociceptin/Orphanin FQ/μ-Opioid Receptor Partial Agonist: Analgesic and Rewarding Properties in Mice
TLDR
The mixed NOP/μ-opioid partial agonist SR 16435 exhibited both NOP and μ-OPioid receptor-mediated behaviors, indicating that both opioid and NOP receptors mediate this behavior.
Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys
TLDR
It is demonstrated that bifunctional MOP/NOP agonists, which may have therapeutic advantages to MOP-selective drugs, can decrease alcohol drinking in nonhuman primates.
Antihyperalgesic effect of buprenorphine involves nociceptin/orphanin FQ peptide-receptor activation in rats with spinal nerve injury-induced neuropathy.
TLDR
Together, buprenorphine suppresses neuropathic hyperalgesia by activating NOP and opioid receptors, suggesting its therapeutic usefulness in treatment of neuropathic pain.
Development of nociceptin receptor (NOP) agonists and antagonists
The nociceptin opioid (NOP) receptor is the most recently discovered member of the family of the opioid receptors; its endogenous agonist is the peptide nociceptin. Due to the subsequent elucidation…
Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice.
Pharmacological Investigation of NOP-Related Ligands as Analgesics without Abuse Liability
TLDR
These studies further support the therapeutic potential of NOP-related ligands including selective NOP agonists and bifunctional NOP/MOP agonist as effective analgesics in order to achieve strong pain relief without concerns over abuse and safety.
Activity of new NOP receptor ligands in a rat peripheral mononeuropathy model: potentiation of morphine anti-allodynic activity by NOP receptor antagonists.
Bifunctional opioid/nociceptin hybrid KGNOP1 effectively attenuates pain‐related behaviour in a rat model of neuropathy
...
...

References

SHOWING 1-10 OF 50 REFERENCES
In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol.
Evidence for an exclusive antinociceptive effect of nociceptin/orphanin FQ, an endogenous ligand for the ORL1 receptor, in two animal models of neuropathic pain
Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: Pharmacological and genetic evidences
[Nphe1,Arg14,Lys15]Nociceptin‐NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor
TLDR
UFP‐101 is a novel, potent and selective NOP receptor antagonist which appears to be a useful tool for future investigations of the N/OFQ‐NOP receptor system.
The nociceptin/orphanin FQ receptor ligand acetyl-RYYRIK-amide exhibits antagonistic and agonistic properties
Spinal and local peripheral antiallodynic activity of Ro64-6198 in neuropathic pain in the rat
[Phe1psi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 is an agonist of the nociceptin (ORL1) receptor.
Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice
TLDR
ZP120 is a highly potent and selective partial agonist of the NOP receptor with prolonged effects in vivo, about 10 fold more potent and its effects lasted longer than N/OFQ.
[Arg14,Lys15]Nociceptin, a Highly Potent Agonist of the Nociceptin/Orphanin FQ Receptor: in Vitro and in Vivo Studies
TLDR
The present data demonstrate that [Arg14,Lys15]NC behaves as a highly potent agonist of the OP4 receptor and is able to produce long-lasting effects in vivo, compared with the natural ligand NC.
Orphanin FQ acts as a supraspinal, but not a spinal, anti‐opioid peptide
TLDR
The findings indicate that the anti-opioid actions of OFQ are restricted to supraspinal central nervous system sites, and not to systemic morphine antinociception induced by i.c.t. morphine.
...
...